MSB

2.58%

94.5¢ mesoblast limited

FDA ODAC Meeting Material discussion analysis, page-51

First 51 Last

Share
Profile

Follow
willious

1,480 Posts.

132

11/08/20

18:47

Post #: 46463216
Share

Originally posted by whenwill ↑

I wanted to see what previous instances of the FDA going against the ODAC Adcom voting and the eventual outcome looked like.

Found that it's only happened 6 times.

Looks like we have a real shot being a novel treatment!

The review was published last week: https://link.springer.com/article/10.1007/s43441-020-00194-4

Does anyone have access to the springer portal and the full review? And maybe links to the actual six instances in question?

Disagreements Between FDA and its Oncologic Drugs Advisory Committee (ODAC)

Abstract

Cases of discordance between the US Food and Drug Administration (FDA) and its advisory committees are uncommon. Due to the importance of oncology therapies, we sought to identify and discuss instances of disagreement between the regulatory decision made by FDA, and the recommendation made by its Oncologic Drugs Advisory Committee (ODAC) via committee vote. Public databases (Oncologic Drugs Advisory Committee Meeting Materials, Drugs@FDA) as well as publicly available documents from ODAC meetings were reviewed to discern cases of disagreement between the two bodies. This review of public data yielded six (6) instances in which FDA’s ultimate regulatory decision went against the recommendation of the ODAC. The six cases are briefly discussed and key drivers for or against an approval decision are outlined. In cases where FDA’s decision was less conservative than that of the ODAC, the value of therapies with novel mechanisms of action which provide new options for patients, as well as regulatory precedent were observed as key drivers for regulatory decision-making. In cases where FDA took a more conservative approach than the ODAC, the importance of appropriate clinical trial design, clinically relevant trial endpoints, and the integrity of the data collected were stressed as driving the ultimate regulatory decision.

Expand

Quite an interesting paper and worth the read. I have access to it, but you have pretty much summarised it there. This is a list of the six mentioned:

MSB Price at posting: $3.36 Sentiment: Buy Disclosure: Not Held
10 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

There are more pages in this discussion • 441 more messages in this thread...

First 51 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 94.5¢		Change -0.025(2.58%)		Mkt cap ! $1.078B

Open	High	Low	Value	Volume
98.0¢	98.5¢	94.0¢	$2.482M	2.602M

Buyers (Bids)

No.	Vol.	Price($)
6	71720	94.0¢

Sellers (Offers)

Price($)	Vol.	No.
94.5¢	10463	1

View Market Depth

No.	Vol.	Price($)
5	65720	0.940
3	31070	0.935
4	85753	0.930
2	9000	0.925
5	75776	0.920

Price($)	Vol.	No.
0.945	10463	1
0.950	50000	2
0.955	64000	1
0.960	30220	3
0.965	44050	3

Last trade - 16.10pm 06/09/2024 (20 minute delay)

MSB (ASX) Chart

FDA ODAC Meeting Material discussion analysis, page-51

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

Shekel Brainweigh investor presentation webinar – the future of retail automation

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

FDA ODAC Meeting Material discussion analysis, page-51

Top Stories

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

Shekel Brainweigh investor presentation webinar – the future of retail automation

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News